Takeda Pharmaceutical Company Ltd

The U.S. FDA has approved GAMMAGARD LIQUID ERC as the only ready-to-use liquid immunoglobulin therapy with low IgA content for primary immunodeficiency treatment in patients aged two and older.

Day One Biopharmaceuticals has appointed Michael Vasconcelles, M.D., as Head of Research and Development, bringing over 25 years of oncology research and development expertise to the company.

RGX-121, a one-time gene therapy using AAV vector technology, is expected to receive regulatory approval in the second half of 2025, potentially offering lifelong benefits from a single infusion for Hunter Syndrome patients.

GC Biopharma's Phase 3 clinical trial results for Hunterase (idursulfase beta) in Hunter Syndrome patients have been published in Genetics in Medicine, demonstrating significant improvements in functional mobility and metabolic markers.

Vima Therapeutics launched with $60 million Series A funding led by Atlas Venture to advance VIM0423, a potential first-in-class oral therapy for dystonia targeting muscarinic cholinergic receptors.

XOMA Royalty Corporation purchased BioInvent's future mezagitamab royalty and milestone rights for $20 million upfront plus $10 million upon FDA approval in IgA nephropathy.

The Alzheimer's drug development landscape has expanded significantly beyond anti-amyloid antibodies, with 88 different clinical trials currently recruiting patients and twelve Phase 3 trials expected to report results in 2025.

NextCell Pharma has appointed Dr. Eric Strati, former executive at Takeda, Mesoblast, and Novartis, to its Board of Advisors to advance commercial strategy for ProTrans, its type 1 diabetes cell therapy.

The New England Journal of Medicine published data showing Takeda's investigational oral orexin receptor 2 agonist oveporexton demonstrated significant improvements in wakefulness and reduced cataplexy events in narcolepsy type 1 patients.

Yaqrit has appointed Ronen Israel, a healthcare innovator and hedge fund strategist, to its management board, strengthening North American investment connectivity for its advanced liver disease portfolio.